Evidence map›Paper›PMID 39961810›Full record

ArticleEuropean biophysics journal : EBJ2025

A paradigm shift: analytical ultracentrifugation as a multi-attribute platform method in targeted protein degradation.

Alexander E Yarawsky, Judith A Ronau, Tiffany A Thibaudeau, Aaron C Ehlinger, Gekleng Chhor, Suki M Hyman, Michelle A Estrada, Vladimir Stojkovic, Michael T DeLion, Anil Vasudevan and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in European biophysics journal : EBJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alexander E Yarawsky *BioAnalysis, LLC, 3401 I Street Suite 206, Philadelphia, PA, 19134, USA.
Judith A Ronau *Technology & Therapeutic Platforms, AbbVie Inc., 1 North Waukegan Rd, North Chicago, IL, 60064, USA. judith.ronau@abbvie.com.
Tiffany A ThibaudeauTarget Enabling Technologies, AbbVie Inc., 1 North Waukegan Rd, North Chicago, IL, 60064, USA.
Aaron C EhlingerTarget Enabling Technologies, AbbVie Inc., 1 North Waukegan Rd, North Chicago, IL, 60064, USA.
Gekleng ChhorTarget Enabling Technologies, AbbVie Inc., 1 North Waukegan Rd, North Chicago, IL, 60064, USA.
Suki M HymanBioAnalysis, LLC, 3401 I Street Suite 206, Philadelphia, PA, 19134, USA.
Michelle A EstradaTechnology & Therapeutic Platforms, AbbVie Inc., 1 North Waukegan Rd, North Chicago, IL, 60064, USA.
Vladimir StojkovicTarget Enabling Technologies, AbbVie Inc., 1 North Waukegan Rd, North Chicago, IL, 60064, USA.
Michael T DeLionBioAnalysis, LLC, 3401 I Street Suite 206, Philadelphia, PA, 19134, USA.
Anil VasudevanTechnology & Therapeutic Platforms, AbbVie Inc., 1 North Waukegan Rd, North Chicago, IL, 60064, USA.
Justin M ReitsmaTechnology & Therapeutic Platforms, AbbVie Inc., 1 North Waukegan Rd, North Chicago, IL, 60064, USA.
Scott E WarderTechnology & Therapeutic Platforms, AbbVie Inc., 1 North Waukegan Rd, North Chicago, IL, 60064, USA.
Lake N PaulBioAnalysis, LLC, 3401 I Street Suite 206, Philadelphia, PA, 19134, USA. lpaul@bioanalysisllc.com.ORCID http://orcid.org/0000-0001-8500-8367

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted protein degradation (TPD) has garnered appreciable interest in drug discovery due to its unique mechanism of action - degradation of a target in an event-driven manner, instead of traditional occupancy-driven inhibitor-based therapies. This is achieved by employing mono- or hetero-bifunctional small molecules known as degraders to induce the proximity of two proteins: a target protein and an E3 ubiquitin ligase, ultimately resulting in clearance of the target protein by the cell's inherent degradation machinery. A critical step in this pathway is ternary complex formation (TCF) between the ligase, degrader molecule, and the target protein. Although a bevy of biochemical, biophysical, cellular and structural approaches have been used to characterize degrader-induced ternary complexes, several knowledge gaps remain, such as stoichiometry and how much ternary complex is formed in solution. Analytical ultracentrifugation (AUC) is a biophysical method that is uniquely suited to address these questions, yet to this point has been surprisingly overlooked as an ideal method to characterize degrader candidates. In this study, we leveraged sedimentation velocity AUC (SV-AUC) to profile the degrader-induced ternary complex formation between Bruton's tyrosine kinase (BTK) and Cereblon (CRBN), allowing for evaluation of multiple attributes including sample purity, percent ternary complex, binding and kinetic rate constants, and hydrodynamics. We show that sedimentation equilibrium AUC (SE-AUC) can further complement the SV-AUC data with accurate molecular weight estimates of the ternary complex to confirm stoichiometry. This work demonstrates that AUC can be used both as a highly informative platform method for rapid characterization of candidate degrader compounds and as a rigorous method for elucidating additional details of the system.

Indexed as

ProteolysisUltracentrifugationAdaptor Proteins, Signal TransducingHumansProtein-Tyrosine KinasesUbiquitin-Protein LigasesAdaptor Proteins, Signal TransducingCRBN protein, humanProtein-Tyrosine KinasesUbiquitin-Protein LigasesBiophysicsDegraderEquilibriumKineticsSEDANALTernary complex formation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.